Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of VX-828 in Healthy Subjects and Cystic Fibrosis
NCT06154447Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-828 in cystic fibrosis (CF) (8 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Maximum Observed Concentration of VX-828 in Plasma and 3 more. Started Dec 2023; status: completed.
02
Drugs
VX-828
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06154447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154447.